Back
Top 56%
11.2%
Top 4%
6.1%
Top 5%
6.1%
Top 50%
5.6%
Top 1%
5.3%
Top 4%
3.7%
Top 4%
3.7%
Top 5%
3.7%
Top 1%
3.0%
#1
3.0%
Top 39%
1.8%
Top 51%
1.8%
Top 2%
1.5%
Top 3%
1.5%
Top 4%
1.4%
Top 17%
1.1%
Top 12%
0.9%
Top 12%
0.9%
Top 3%
0.9%
Top 5%
0.7%
Top 15%
0.7%
Real-world evidence of triplet therapy in metastatic hormone-sensitive prostate cancer - an Austrian multicenter study
2023-10-14
urology
Title + abstract only
View on medRxiv
Show abstract
IntroductionTwo randomized trials demonstrated a survival benefit of triplet therapy (androgen deprivation therapy [ADT]) plus androgen receptor pathway inhibitor [ARPI] plus docetaxel) over doublet therapy (ADT plus docetaxel) changing treatment strategies in metastatic hormone-sensitive prostate cancer (mHSPC). Patients and methodsWe conducted the first real-world analysis including 97 mHSPC patients from sixteen Austrian medical centers. 79.4% of patients received abiraterone, 17.5% daroluta...
Predicted journal destinations
1
PLOS ONE
1737 training papers
2
Cancers
57 training papers
3
eLife
262 training papers
4
Scientific Reports
701 training papers
5
Cureus
64 training papers
6
Frontiers in Oncology
34 training papers
7
Frontiers in Medicine
99 training papers
8
JAMA Network Open
125 training papers
9
BMC Cancer
21 training papers
10
Journal of Translational Medicine
21 training papers
11
Nature Communications
483 training papers
12
BMJ Open
553 training papers
13
Diagnostics
36 training papers
14
Journal of Clinical Investigation
50 training papers
15
Clinical Cancer Research
22 training papers
16
Journal of Clinical Medicine
77 training papers
17
Vaccines
131 training papers
18
Frontiers in Immunology
140 training papers
19
Science Translational Medicine
40 training papers
20
British Journal of Cancer
22 training papers
21
Heliyon
57 training papers